The Translational Initiative to Map Epigenetics in Aging (TIME-A)
ConditionBiological Aging
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorElysium Health
About this trial
The Translational Initiative to Map Epigenetics in Aging (TIME-A) study aims to advance our understanding of the connections between epigenetics, lifestyle, demographics, and health and aging.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
All adults aged 18 and above
Have registered at least one Index kit via the Elysium Health website
Able and willing to provide digital consent to the Research Consent Form, and the TIME-A Research Subject Consent Form
Disqualifiers
Consent to participate not given
Trial population
Adults 18 or older
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
25,000 Participants
are grouped into 1 trial groupGroup A: TIME-A
Trial outcomes
Primary outcomes
1
Effect of environmental and lifestyle factors on biological age
Univariate and multivariate statistical methods will be used to identify which environmental and lifestyle factors (from TIME-A survey responses) influence biological age.
Time frame
At baseline and throughout study (approximately every 6 months up to 120 months)2
Effect of general health on biological age
Univariate and multivariate statistical methods will be used to identify which general health characteristics (from TIME-A survey responses) influence biological age.
Time frame
At baseline and throughout study (approximately every 6 months up to 120 months)3
Effect of medical history on biological age
Univariate and multivariate statistical methods will be used to identify the impact of medical history (from TIME-A survey responses) on biological age.
Time frame
At baseline and throughout study (approximately every 6 months up to 120 months)Other outcomes
1
Develop epigenetic signatures that are predictive of health status
DNA methylation data and TIME-A survey responses will be combined. Supervised and unsupervised machine learning methods will be used to generate novel methylation-derived predictors of participants' survey responses.
Time frame
At baseline and throughout study (approximately every 6 months up to 120 months)Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: